Our prior study in multiple myeloma (MM) patients showed increased numbers of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM), which both contribute to immune dysfunction as well as promote tumor cell growth, survival and drug resistance. Here we show that a novel Toll-like receptor (TLR-9) agonist C792 restores the ability of MM patient-pDCs to stimulate T-cell proliferation. Coculture of pDCs with MM cells induces MM cell growth; and importantly, C792 inhibits pDC-induced MM cell growth and triggers apoptosis. In contrast, treatment of either MM cells or pDCs alone with C792 does not affect the viability of either cell type. In agreement with our in vitro data, C792 inhibits pDC-induced MM cell growth in vivo in a murine xenograft model of human MM. Mechanistic studies show that C792 triggers maturation of pDCs, enhances interferon-a and interferon-l secretion and activates TLR-9/MyD88 signaling axis. Finally, C792 enhances the anti-MM activity of bortezomib, lenalidomide, SAHA or melphalan. Collectively, our preclinical studies provide the basis for clinical trials of C792, either alone or in combination, to both improve immune function and overcome drug resistance in MM.
INTRODUCTION
Multiple myeloma (MM) remains incurable due to the development of drug resistance mediated by mechanisms intrinsic to the tumor cells as well as interaction of MM cells with the accessory cells in the bone marrow (BM) microenvironment. [1] [2] [3] BM stromal cells, osteoclasts, osteoblasts, myeloid cells and immune effector cells, that is, myeloid-derived suppressor cells, can promote growth and drug resistance in MM cells. [4] [5] [6] Research efforts are now focused on defining the functional significance of tumor cell interaction with BM accessory cells in the MM niche to identify novel therapeutic strategies.
Dendritic cells (DCs) 7, 8 mediate immune function and promote tumor growth. [9] [10] [11] Human DCs have been classified into two major subtypes [12] [13] [14] based on the their origin, phenotype and function: myeloid DCs and plasmacytoid DCs (pDCs). myeloid DCs have been extensively characterized, [12] [13] [14] [15] [16] and recent studies have also begun to characterize pDCs and their functionality. pDCs express CD123, CD303, CD304 and HLA-DR, and lack lineage cell markers for B, NK and T cells, as well as monocytes. The antigen presenting function of pDCs is, at least in part, mediated via Toll-like receptors (TLRs; TLR7 and TLR9), which recognize viral RNA template or unmethylated bacterial DNA, thereby facilitating secretion of Type I and Type II interferons (IFN). [17] [18] [19] These pleiotropic cytokines in turn activate multiple components of the immune system including T cells, B cells and NK cells. Early reports 20, 21 showed that pDCs from MM patients are defective in their antigenpresenting function; indeed, the loss of immune function of tumor-infiltrating DCs has been linked to suppressive effects of the tumor microenvironment in multiple cancers, including MM. 22, 23 Besides generating an antiviral immune response, pDCs also have a role in normal B-cell development into plasmablasts, differentiation into antibody-secreting plasma cells and survival. [24] [25] [26] [27] In this context, our recent study defined the role of pDCs in regulating growth and survival of malignant plasma (MM) cells. 28 Specifically, we found increased numbers of pDCs in the MM BM microenvironment, which both mediate immune deficiency characteristic of MM, as well as promote tumor cell growth, survival and drug resistance. In the present study, we show that a novel TLR-9 agonist C792 29 both restores pDC immune function and inhibits pDC-induced MM cell growth and drug resistance. Our study provides the basis for targeting pDC-MM interactions using TLR9 agonist C792 as a potential therapeutic strategy in MM.
MATERIALS AND METHODS

Isolation and phenotypic analysis of pDCs
Studies involving patient MM cells were performed following IRB-approved protocols at Dana-Farber Cancer Institute and Brigham and Women's Hospital (Boston, MA, USA). Informed consent was obtained, and the samples were de-identified before experimental use. pDCs were isolated from both BM and peripheral blood mononuclear cells by magnetically activated cell sorting using CD304 (BDCA-4/Neuropilin-1) microbeads kit (Miltenyi Biotec, Auburn, CA, USA), as previously described. 28 Briefly, mononuclear cells from healthy donors and MM patients were isolated by Ficoll Hypaque density gradient centrifugation, magnetically labeled with anti-BDCA-4 antibody (Miltenyi Biotec) coupled to colloidal paramagnetic microbeads and passed through a magnetic separation column twice. Cells lacking lineage markers and CD11c were FACS sorted. The purity of pDCs was confirmed by staining of cells with CD123 PE-Cy5, HLA-DR Pacific Blue and BDCA-2 FITC (X99% purity). 30 The CD304-positive pDCs obtained by this method are lineage negative Lin-1 (CD3, CD14, CD19, CD20, CD56 and CD11c negative), MHC II positive and CD123/BDCA-2 positive. pDCs were also purified by negative depletion using LD columns (Miltenyi Biotec; 99% BDCA2 þ CD123 þ cells). Cells were sorted using FACS Aria II cell sorter, and all flow cytometric experiments were performed using BD Canto II or BD LSRFortessa machine (BD Biosciences, San Jose, CA, USA). Data were analyzed using a FACS DIVA (BD Biosciences) and FlowJO software (ver 7.6.5, Tree Star Inc., Ashland, OR, USA).
Cytokines, antibodies and reagents
Human recombinant interleukin (IL)-3 and IL-6 were obtained from Peprotech Inc. (Rocky Hill, NJ, USA). Recombinant IFN-a, IFN-l and DR5-Alexa700 were purchased from R&D Systems (Minneapolis, MN, USA). CD3-PE; CD4-FITC or APC-Cy7; CD40-FITC; CD80-FITC; CD83-FITC; CD86-FITC; CD123-PE/PE-Cy5; as well as CD138-FITC, PE were obtained from BD Biosciences. HLA-DR Violet Blue, BDCA-2 FITC, CD14-PE and CD11c-APC were purchased from Miltenyi Biotec. TLR-9-FITC, TRAIL-PE and DR-4-FITC were obtained from Abcam. The CpG-C oligodeoxynucleotide C792 was synthesized and purified by standard techniques as previously described; 29 bortezomib, lenalidomide, and SAHA were purchased from Selleck Chemicals LLC (Houston, TX, USA); melphalan was purchased from Sigma Chemical Company (St Louis, MO, USA); and MyD88 inhibitor was purchased from InVivoGen (San Diego, CA, USA). For assessing C792 effect on the viability of freshly isolated pDCs, we cultured cells in DCP-MM medium (MatTek Corp, Ashland, MA, USA).
Cytokine assays IFN-a, IFN-l and soluble TNF-related apoptosis-inducing ligand (sTRAIL) were measured by ELISA using commercially available kits, according to the manufacturer's instructions (PBL Interferon Source, Piscataway, NJ, USA and R&D Systems). Briefly, MM.1S cells (5 Â 10 4 cells/200 ml per well) and pDCs (1 Â 10 4 cells/200 ml per well) were cultured either alone or together at 1:5 (pDC:MM) ratio in 96-well plates, in the presence or absence of C792; supernatants from these cocultures were collected and analyzed for cytokine secretion using ELISA. MM.1S cells were also treated with various concentrations of recombinant hu-IFN-a (R&D Systems) and analyzed for viability by MTT assay.
Flow cytometry and intracellular staining
For flow cytometric analysis, single-cell suspensions were stained with different fluorophore-coupled monoclonal antibodies (BD Biosciences). All flow cytometric analysis was performed on gated populations: CD138 þ fraction for MM cells and CD123 þ /CD304 þ /CD303 þ /HLA-DR þ / CD11C À fraction for pDCs. Activation and maturation of pDCs were assessed by FACS analysis using CD40, CD80, CD83 and CD86 surface markers. Intracellular staining and cell/tissue fixation was assessed using the Cytofix/Cytoperm buffer kit (BD Biosciences) as per manufacturer's instructions.
Cell culture and assessment of cell viability, growth and apoptosis Cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. MM.1S (Dexamethasone sensitive), MM.1R (Dexamethasone resistant), RPMI-8226, Doxorubicin (Dox)-resistant (Dox-40), Melphalan-resistant LR5 and NCI-H929 human MM cell lines were cultured in complete medium. ANBL-6 MM cell line was cultured in complete medium with IL-6 (5 ng/ml). Cell viability was assessed using colorimetric assay with 3-(4, 5-dimethylthiozol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Calbiochem, EMD Millipore, Billerica, MA, USA). 28 MM cell proliferation in coculture experiments with pDCs or BM stromal cells was performed using WST (Clontech Laboratories, Mountain View, CA, USA) assays, as described previously. 28 Briefly, pDCs were cocultured with MM.1S cells at 1:5 pDC/MM.1S ratio in the presence or absence of C792, followed by cell growth analysis using WST assay. T cell proliferation assay: MM pDCs were cultured with or without T cells, in the presence or absence of C792, and proliferation was assessed using WST assays. 23, 28 Cell cycle was analyzed using propidium iodide staining. Apoptosis was quantified using Annexin V-Fitc/Propidium iodide apoptosis detection kit as per manufacturer's instructions (BD Biosciences), followed by analysis on BD FACSCanto II or BD LSRFortessa (BD Biosciences). ) at 1:10 (pDC/T cell) ratio in the presence or absence of C792 (0.1 mg/ml) for 5 days, and then analyzed for T-cell proliferation using WST assay (mean ± s.d.; Po0.01 for all patients).
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RESULTS
C792 stimulates MM patient pDCs to trigger T-cell proliferation
Prior studies have reported immune dysfunction in MM, associated with decreased ability of MM patient BM-DCs to stimulate T-cell proliferation. [21] [22] [23] In our study, we first examined the in vitro function of pDCs 30 (defined as HLA-DR þ , CD123 þ and CD303/BDCA-2 þ cells) derived from normal healthy donors versus MM patients, assessed by their ability to stimulate allogeneic T-cell responses. As shown in Figure 1a , MM pDCs induce significantly decreased T-cell proliferation versus normal pDCs (P ¼ 0.02). We next examined whether treatment of MM patient BM-pDCs with TLR9 agonist (CpG-ODNs) C792 affects their T-cell stimulatory activity. Importantly, C792 restores the ability of MM patient BM-pDCs to induce both allogeneic ( Figure 1a ) and autologus T-cell proliferation ( Figure 1b ). Our data are consistent with other studies showing that targeting TLR9 using agonists can activate pDC, and enhance their immune functions. 17, 18, [32] [33] [34] [35] C792 blocks pDC-induced MM cell growth Recent reports linked increased infiltration of DCs in human tumors with unfavorable prognosis. 6, 10, 36, 37 Our earlier study in MM showed that increased numbers of pDCs in MM patient's BM trigger growth of MM cells. 28 Having shown that C792 restores MM patient BM-pDCs immune function, we next examined whether C792 affects pDC-induced MM cell growth using WST proliferation assays. As shown in Figure 2a , C792 inhibits patient-BM pDC-triggered MM.1S cell proliferation in a dose-dependent manner. Non-CpG ODN 1040 served as negative control. C792 also blocked pDC-induced growth of various other MM cell lines (MM.1R, ANBL-6, RPMI-8226, Dox-40 or LR-5) (Supplementary Figure 1) . These results were also confirmed from an additional cell growth assay, using the CellTrace CFSE Proliferation Kit (data not shown; Life Technologies, Grand Island, NY, USA). No significant growth of pDCs was observed in cocultures of pDCs and MM cells (data not shown). Importantly, C792 treatment of pDCs or MM cell lines alone did not decrease viability of either cell type (Figure 2b and c, respectively) . Similar to our observation using MM cell lines, we next examined whether C792 affects pDC-induced proliferation of patient MM cells using WST proliferation assays. As in our prior study, pDCs triggered proliferation of patient MM cells; and importantly, C792 blocked pDC-induced patient MM cell growth (Figure 2d ). Furthermore, C792 inhibited MM patient BM pDCinduced growth of both autologous tumor cells ( Figure 2e ) and allogeneic MM.1S cell line (Figure 2f ). Taken together, our findings suggest that activation of pDCs with TLR9 agonist C792 both (Figure 3a) , as in our prior study. 28 Importantly (Figure 3a) . Moreover, a marked prolongation of survival (P ¼ 0.002) was noted in mice who received C792-treated pDCs compared with in mice injected with either untreated pDCs plus MM.1S cells or MM.1S cells alone (Figure 3b) . Together, our in vitro and in vivo human MM xenograft studies provide evidence for the anti-MM activity of C792 by virtue of its ability to block pDC-mediated MM cell growth.
Mechanism(s) mediating anti-MM activity of C792 Previous studies reported that CpG-ODNs can activate pDCs. [38] [39] [40] [41] To determine whether C792 similarly activates freshly isolated MM patient pDCs, we treated pDCs with C792 and examined expression of surface markers characteristic of activation and maturation. Treatment of pDCs with C792 increases CD40, CD83, CD80, HLA-DR and CD86 expression (Figure 4a) . Specifically, flow cytometric data showed that C792 triggered a significant increase Targeting Toll-like receptor 9 as myeloma therapy A Ray et al in median fluorescence intensity of CD40, CD83, CD80, HLA-DR and CD86 expression (20, 37, 10, 6 and 13% increase, respectively). Non-CpG 1040 served as a negative control (Figure 4a ). C792 is a TLR9 agonist, and we found a significant increase in TLR9 expression in C792-treated pDCs (Figure 4b , left and right panels).
To further confirm that C792 activates MM patient pDCs, we examined additional mechanism(s) associated with activation of pDCs. For example, prior studies have shown that CpG-ODNactivated pDCs secrete Type I and Type III IFNs; [41] [42] [43] this is exemplified in systemic lupus erythematous, which is linked to TLR-9-activated pDCs and Type I IFN-a release. 18, [33] [34] [35] In view of these studies, we next examined (1) whether treatment of MM patient BM-pDCs with C792 triggers IFN-a secretion; and (2) if IFN-a secretion is attenuated or augmented during pDC-MM cocultures. Treatment of pDCs with C792, but not non-CpG ODN control, triggered an increase in IFN-a secretion (Figure 4c) . Importantly, C792 induced a more robust dose-dependent IFN-a secretion in pDC-MM cocultures versus pDCs alone (Figure 4d ). This phenomenon was also observed in C792-treated normal healthy donor pDC-MM cocultures versus normal pDC alone (data not shown).
IFN-a was undetectable in the supernatant from C792-treated MM cells. Our findings are also consistent with earlier studies 40, 41 demonstrating a non-linear relationship between CpG-ODNs, like C792, and secretion of IFN-a. In addition to Type I IFN-a release, C792 also triggered Type III IFN-l secretion in pDC-MM cocultures, albeit to a lesser extent than IFN-a (Supplementary Figure 2) .
We next examined the signaling mechanism mediating C792-induced IFN-a secretion in MM patient BM pDCs. As stated above, C792 is a TLR9 agonist and upregulates TLR9 expression in pDCs (Figure 4b) . To validate the functionality of TLR9 signaling axis in pDCs, we examined downstream adaptor protein MyD88 (Myeloid differentiation primary response gene). 44, 45 In our study, biochemical inhibition of MyD88 homodimer formation significantly blocked C792-induced IFN-a secretion (Figure 4e ). Together, our findings suggest that the inhibitory effect of C792 on pDC-induced MM cell growth is associated with activation of pDCs via TLR9-MyD88 signaling and release of IFN-a.
Although C792-triggered activation of pDCs, explains the restoration of MM pDC ability to stimulate T-cell responses, it does not elucidate the mechanism whereby C792 inhibits pDCinduced MM cell growth. One possibility is that C792 triggers 3 ) were pretreated with 50 mM of MyD-88 inhibitor peptide for 4 h, followed by addition of C792 for 24 h; supernatants from these cultures were analyzed for IFN-a using ELISA (mean ± s.d.; Po 0.05, n ¼ 3).
Targeting Toll-like receptor 9 as myeloma therapy A Ray et al secretion of soluble factors, which inhibit MM cell growth and/or trigger apoptosis. Interestingly, we found large amounts of IFN-a in C792-treated pDC-MM cocultures; and importantly, IFN-a has been utilized in the treatment of cancers, including MM. [46] [47] [48] We therefore examined whether IFN-a blocks pDC-induced MM cell growth. For these studies, we utilized human recombinant IFN-a at various concentrations, including those that were obtained in supernatants from C792-treated pDC-MM cocultures (Figure 4d ). pDCs were cocultured with MM cell lines (MM.1S, MM.1R, LR-5 and NCI-H929) in the presence or absence of rIFN-a, followed by analysis of cell growth. A dose-dependent decrease in the pDCinduced MM cell growth was noted in response to treatment with rIFN-a (Figure 5a , and data not shown). These findings suggest that IFN-a, at least in part, mediates the anti-MM activity of C792.
Previous studies have linked TLR9-stimulated pDCs to TRAIL, which binds to cells expressing TRAIL receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) and results in apoptosis. 49, 50 We next examined whether C792 induces secretion of sTRAIL from pDCs. A significant increase in sTRAIL was present in supernatants from C792-treated-versus untreated-pDC-MM cocultures (Figure 5b; Po0.005). As MM cells express TRAIL receptors DR4 and DR5, 51 and our findings show that C792 induce sTRAIL (Figure 5b) , it is likely that TRAIL-TRAIL-R interactions mediate anti-MM activity of C792. We do not exclude the possibilty that other factors besides IFN-a or sTRAIL may also mediate MM cell cytotoxicity of C792 in pDC-MM cultures, as we found that supernatants from C792-treated pDC-MM cocultures triggered a marked decrease in MM cell viability (Figure 5c ).
We next examined whether MM cell growth inhibition in C792-treated pDC-MM cocultures is due to cell cycle alterations and/or apoptosis in MM cells. Treatment of pDC-MM cocultures with C792 is associated with growth arrest in MM.1S cells: specifically, cell cycle analysis of CD138 þ MM cells obtained from pDC-MM.1S cocultures showed increased G2 phase in C792-treated-versus untreated-pDC-MM cocultures (Figure 5d ). Of note, treatment of MM cells without pDCs does not affect the cell cycle profile of MM cells; consistent with our finding that C792 is not cytotoxic against MM cells alone (Figure 2c) . Finally, we show that treatment of pDC-MM cocultures with C792 triggers MM cell apoptosis (Figure 5e ). Targeting Toll-like receptor 9 as myeloma therapy A Ray et al definitive evidence of decreased toxicity of combination therapy awaits results of clinical trials, the synergy observed in vitro may allow for use of lower doses and reduced toxicity.
DISCUSSION
Our previous study identified an integral role of pDCs in MM pathogenesis. 28 Specifically, using our in vitro and in vivo models of human MM in the BM milieu, we showed that increased numbers of pDCs in the MM BM confer growth, survival, chemotaxis and drug resistance. In addition, we found a decreased ability of MM BM pDCs versus normal pDCs to trigger T-cell proliferation. 28 A similar immune dysfunction in MM-pDCs has been noted in other reports. 20, 21 Earlier studies have shown promising activity of immunostimulatory CpG-based formulations as immune adjuvants in vaccines or in the treatment of viral, bacterial and parasitic infections, as well as in cancers. 29 Indeed, both Type A and Type B CpG ODNs have been evaluated in clinical trials. 52 In the current study we examined whether C792, a novel next generation Type-C CpG-ODN targeting TLR9 with a potent immune-enhancing activity, affects pDC-induced MM cell growth and/or stimulates pDC immune function. Our data show that treatment of MM BM pDCs with C792 restores their ability to stimulate both autologous and allogeneic T-cell proliferation. A previous study using the B16 mouse melanoma tumor model also showed that CpG-activated pDCs induce a systemic antitumor immunity through activation of NK cells and T cells. 35 Further studies are required to determine whether C792-activated MM pDCs generate antitumor immunity, which is clinically significant in MM.
Importantly, we found that C792 inhibits pDC-induced growth of various MM cell lines, including those sensitive and resistant to various conventional and novel therapies, as well as representing distinct cytogenetic subtypes. 53, 54 For example, we studied isogenic cell lines Dex-sensitive MM.1S and Dex-resistant MM.1R with t(14;16) translocation, as well as RPMI-8266 parental and Doxorubicin-resistant (8226/Dox-6) or melphalan-resistant (LR5) derivative cell lines. Similar findings were observed using MM cells from patients with relapsed MM refractory to various therapies. Importantly, C792 blocked MM patient BM pDC-induced growth of both autologous tumor cells and allogeneic MM.1S cell line. Our data therefore highlight the ability of C792 to overcome genetic heterogeneity and broadly inhibit pDC-induced growth in MM. Interestingly, treatment of MM cells or pDCs alone with C792 does not affect their viability; the MM cell growth inhibitory activity of C792 is only observed in the pDC-MM coculture setting. This finding confirms the role of factors and/or MM BM accessory cells within the MM BM milieu, in this case pDCs, to impact the sensitivity versus resistance of MM cells. There is an urgent need to clinically evaluate novel agents targeting the tumor cell in the BM microenvironment, and clinical trials of C792 will provide proof of principle.
In agreement with our in vitro data, C792 also inhibited pDCtriggered MM cell growth in vivo. More rapid tumor growth occurred in mice receiving both pDCs and MM cells versus MM cells alone; and importantly, mice receiving C792-treated pDCs plus MM cells showed significantly reduced tumor growth. The prolonged survival of pDCs in our xenograft model may be explained by our earlier study 28 showing: (1) that pDC-MM cell interactions trigger secretion of IL-3, a survival factor for pDCs; 14 and (2) increased IL-3 and pDCs (BDCA-2-positive cells) in tumor sections from mice receiving pDCs and MM cells versus MM cells alone. Our ongoing studies using C792 are now evaluating the effects of C792 on IL-3 and other cytokines/chemokines secreted during pDC-MM interactions. Together, our findings from both in vitro and human MM xenograft in vivo models suggest that C792 inhibits pDC-induced MM cell growth, and provide the basis for targeting pDC-MM interactions as a therapeutic strategy in MM.
Treatment with C792 is associated with activation/maturation of pDCs, evidenced by upregulation of CD83, CD40, CD80, CD86 and HLA-DR, as well as IFN-a release. Indeed, C792 targets TLR-9 to trigger both pDCs activation and release of IFN-a. Moreover, the enagagement of TLR9 by C792 activates downstream signaling via adaptor protein MyD88; conversely, blockade of MyD88 inhibited C792 activity, evidenced by a marked decrease in IFN-a secretion from pDCs. Enhanced IFN-a secretion in response to C792 may explain, at least in part, cytotoxicity of C792 against MM cells in pDC-MM cocultures. Indeed, previous studies have shown cytotoxic activity of IFN-a against MM cells, [46] [47] [48] and clinical trials have shown anti-MM activity of IFN-a, either as a single agent or in combination. In addition to IFN-a, we also found sTRAIL in the supernatants from C792-treated pDC-MM cocultures, which may interact with TRAIL-R expressed on MM cells and trigger MM cell death.
Finally, we show that C792 triggers synergistic anti-MM activity with current anti-MM agents including proteasome inhibitor bortezomib, immunomodulatory agent lenalidomide, HDAC inhibitor SAHA or alkylating agent melphalan. Most of these agents trigger a direct cytotoxic effect on MM cells, and combination trials with C792 will allow not only targeting MM cells, but also bolster the immune response in MM patients.
Collectively, we show that targeting TLR9 with CpG ODN C792 improves immune function of pDCs on the one hand and blocks pDC-induced MM cell growth on the other. Our preclinical study provides the framework for clinical trials of C792, either alone or in combination, to improve immune function, enhance cytotoxicity, overcome drug resistance and improve patient outcome in MM.
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